Project partners

The project consortium consists of 25 partners from 12 countries and more than 200 researchers are currently working on the project.

Successful development of protein kinase inhibitors requires a multidisciplinary approach. The consortium includes academic groups with unique expertise in biochemistry, structural crystallography, synthetic organic chemistry, lead structure optimisation and other fields of rational drug discovery.

University of Helsinki
Faculty of Pharmacy
Division of Pharmacology and Toxicology and
Viikki Drug Discovery Technology Center (DDTC)

Prof. Raimo K. Tuominen (project coordinator)
Prof. Jari Yli-Kauhaluoma

and
Faculty of Agriculture and Forestry, Department of Applied Chemistry and Microbiology
Prof. Kaarina Sivonen
Prof. Annele Hatakka

Helsinki, Finland
 CNRS Lyon
Méthodologies de Synthèse
et Molécules Bioactives,
Université Claude Bernard Lyon 1

Prof. Peter Goekjian
Prof. Hélène Parrot-Lopez
Prof. Benoît Joseph
Prof. Olivier Piva
Dr. Philippe Belmont
and
Université Blaise Pascal - Clermont-Ferrand II
Prof. Michelle Prudhomme
France
The Hebrew University of Jerusalem
- Hadassah Medical School


Prof. Charles L. Jaffe
Prof. Alexander Levitzki
Jerusalem, Israel
Ludwig Maximilians University Munich
Department of Pharmacy

Prof. Angelika Vollmar
Dr. Stefan Zahler
München, Germany
Université de Genève
Laboratoire de Pharmacognosie et de Phytochimie
Section des Sciences Pharmaceutiques

Prof. Andrew Marston
Geneva, Switzerland
Université de Genève
Laboratoire de chimie thérapeutique
Section de pharmacie

Prof. Leonardo Scapozza
Geneva, Switzerland
University of Dundee
School of Life Sciences

Prof. Sir Philip Cohen
Scotland, UK
University of Birmingham
Department of Immunology

Prof. Janet M. Lord
Birmingham, UK
University of Debrecen
Medical and Health Science Center
Department of Biophysics and Cell Biology

Prof. János Szöllõsi
Prof. György Vereb
Debrecen, Hungary
University of Milano-Bicocca

Professor of Internal Medicine
Prof. Carlo Gambacorti-Passerini

Monza, Italy
 
University of Innsbruck
Institute of Pharmacy

Prof. Thierry Langer
Innsbruck, Austria
KTB Tumorforschungs GmbH
ProQinase


Dr. Michael Kubbutat
Freiburg, Germany
CR-UK London Research Institute

Prof. Peter J. Parker
Dr. Neil Mcdonald
London, UK
CNRS Roscoff, Station Biologique

Prof. Laurent Meijer
Roscoff, France
C3Biotech

Dr. Paul Pechan
Otterfing, Germany
Neurokin S.A.R.L.

Dr. Serge Timsit
Dr. Benedicte Menn
Marseilles, France
Venetian Institute for Molecular Medicine (VIMM)
and University of Padova,
Departments of Biological Chemistry
and Organic Chemistry

Prof. Lorenzo A. Pinna
Prof. Giuseppe Zanotti
Padova, Italy
University of Oxford
Department of Biochemistry

Prof. Dame Louise Johnson
Dr. Aude Echalier
Dr. Jane A. Endicott
Dr. James McDonnell
Dr. Martin E.M. Noble
Oxford, UK
University of Bergen
Apoptosis Signaling Group (APSIB)

Prof. Stein-Ove Døskeland
Bergen, Norway
Institute of Neurobiology
of the Mediterranean Sea
(INMED / INSERM)

Dr. Yehezkel Ben-Ari
Dr. Anton Ivanov
Marseille, France
Inte:Ligand
Software Development Unit

Dr. Gerhard Wolber
Vienna, Austria
Pepscan Systems BV

Dr. Peter van Dijken
Dr. Jos Joore
Lelsyatd, The Netherlands
Technische Universität Braunschweig
Institut für Pharmazeutische Chemie

Prof. Conrad Kunick
Braunschweig, Germany
Innsbruck Medical University
Institute of Medical Chemistry and Biochemistry

Prof. Johann Hofmann
Innsbruck, Austria
University of Vienna
Department of Pharmacognosy

Prof. Verena M. Dirsch, Ph.D
Vienna, Austria
Gause Institute of New Antibiotics

Prof. Maria N. Preobrazhenskaya
Moscow, Russia
Research Center fro Biotechnology of Antibiotics

Prof. Valery Danilenko
Moscow, Russia